PDL-1 Expression and Survival in Metastatic Non-small Cell Lung Cancer Patients Who Received Chemotherapy as First-Line Treatment.

IF 0.8 Q4 RESPIRATORY SYSTEM

Turkish Thoracic Journal Pub Date : 2022-01-01 DOI:10.5152/TurkThoracJ.2021.21151

Pınar Gursoy, Burcu Çakar, Damla Gunenc, Deniz Nart, Akın Çınkooğlu, Nuran Katgı

{"title":"PDL-1 Expression and Survival in Metastatic Non-small Cell Lung Cancer Patients Who Received Chemotherapy as First-Line Treatment.","authors":"Pınar Gursoy, Burcu Çakar, Damla Gunenc, Deniz Nart, Akın Çınkooğlu, Nuran Katgı","doi":"10.5152/TurkThoracJ.2021.21151","DOIUrl":null,"url":null,"abstract":"Objective: To show the effect of programmed cell death protein-1ligand (PDL-1) level on survival times in patients with metastatic non-small cell lung cancer (mNSCLC) receiving chemotherapy, to determine the relationship between PDL-1 level, neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR).Material and methods: The data of 158 patients who received chemotherapy for mNSCLC were evaluated retrospectively. Clinical and demographic data, PDL-1 expression levels and follow-up periods of the patients were recorded. The patients were divided into 2 groups according to PDL-1 levels.Results: In all patients, progression free survival (PFS) was 5.6 months and overall survival (OS) was 18.8 months. Patients with low PDL-1 had a longer PFS than patients with high PDL-1 (p:0.038). In the gemcitabine and taxane groups, patients with low PDL-1 had a longer PFS than patients with high PDL-1 (p:0.047). There was a significant correlation between NLR and PDL-1 levels. In the groups with high PDL-1, patients with low NLR levels had higher OS than patients with high NLR level (p:0.043). Also, there was a significant difference between the OS patients with low and high PLR levels (p:0.520).Conclusion: In patients with mNSCLC whose PDL-1 levels and NLR levels are low, immunogenic chemotherapies such as gemcitabine and taxane can be tried as an alternative treatment.","PeriodicalId":37452,"journal":{"name":"Turkish Thoracic Journal","volume":"23 1","pages":"45-51"},"PeriodicalIF":0.8000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f7/7d/ttj-23-1-45.PMC9450090.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Thoracic Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5152/TurkThoracJ.2021.21151","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To show the effect of programmed cell death protein-1ligand (PDL-1) level on survival times in patients with metastatic non-small cell lung cancer (mNSCLC) receiving chemotherapy, to determine the relationship between PDL-1 level, neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR).

Material and methods: The data of 158 patients who received chemotherapy for mNSCLC were evaluated retrospectively. Clinical and demographic data, PDL-1 expression levels and follow-up periods of the patients were recorded. The patients were divided into 2 groups according to PDL-1 levels.

Results: In all patients, progression free survival (PFS) was 5.6 months and overall survival (OS) was 18.8 months. Patients with low PDL-1 had a longer PFS than patients with high PDL-1 (p:0.038). In the gemcitabine and taxane groups, patients with low PDL-1 had a longer PFS than patients with high PDL-1 (p:0.047). There was a significant correlation between NLR and PDL-1 levels. In the groups with high PDL-1, patients with low NLR levels had higher OS than patients with high NLR level (p:0.043). Also, there was a significant difference between the OS patients with low and high PLR levels (p:0.520).

Conclusion: In patients with mNSCLC whose PDL-1 levels and NLR levels are low, immunogenic chemotherapies such as gemcitabine and taxane can be tried as an alternative treatment.

Abstract Image

查看原文本刊更多论文

接受化疗作为一线治疗的转移性非小细胞肺癌患者的PDL-1表达和生存率。

目的:探讨程序性细胞死亡蛋白-1配体(PDL-1)水平对转移性非小细胞肺癌(mNSCLC)化疗患者生存时间的影响，探讨PDL-1水平与中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)的关系。材料与方法:回顾性分析158例小细胞肺癌化疗患者的资料。记录患者的临床及人口学资料、PDL-1表达水平及随访时间。根据PDL-1水平将患者分为两组。结果:所有患者无进展生存期(PFS)为5.6个月，总生存期(OS)为18.8个月。低PDL-1患者的PFS较高PDL-1患者长(p:0.038)。在吉西他滨和紫杉烷组中，低PDL-1的患者比高PDL-1的患者的PFS更长(p:0.047)。NLR与PDL-1水平有显著相关性。在高PDL-1组中，低NLR患者的OS高于高NLR患者(p:0.043)。此外，低PLR水平和高PLR水平的OS患者之间存在显著差异(p:0.520)。结论:对于PDL-1水平和NLR水平较低的小细胞肺癌患者，可尝试免疫原性化疗如吉西他滨和紫杉烷作为替代治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Turkish Thoracic Journal Medicine-Pulmonary and Respiratory Medicine

CiteScore

1.40

自引率

11.10%

发文量

期刊介绍： Turkish Thoracic Journal (Turk Thorac J) is the double-blind, peer-reviewed, open access, international publication organ of Turkish Thoracic Society. The journal is a quarterly publication, published on January, April, July, and October and its publication language is English. Turkish Thoracic Journal started its publication life following the merger of two journals which were published under the titles “Turkish Respiratory Journal” and “Toraks Journal” until 2007. Archives of both journals were passed on to the Turkish Thoracic Journal. The aim of the journal is to convey scientific developments and to create a dynamic discussion platform about pulmonary diseases. With this intent, the journal accepts articles from all related scientific areas that address adult and pediatric pulmonary diseases, as well as thoracic imaging, environmental and occupational disorders, intensive care, sleep disorders and thoracic surgery. Clinical and research articles, reviews, statements of agreement or disagreement on controversial issues, national and international consensus reports, abstracts and comments of important international articles, interesting case reports, writings related to clinical and practical applications, letters to the editor, and editorials are accepted.